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AGEs bind to mesothelial cells via RAGE and stimulate risk of peritoneal infection. Improvement in delivery sys-
VCAM-1 expression. tems has since reduced the overall rate of infection, and
Background. Excess advanced glycation end-products (AGEs) the number of patients who have been continuouslyare formed during renal failure, and AGE formation also may
treated by PD for over five or ten years has markedly in-be connected with the high glucose concentration of peritoneal
dialysis (PD) fluids. To determine the effect of human perito- creased. Sclerosing syndromes and membrane failure are
neal mesothelial cell (HPMC) exposure to glycated proteins, the most common complications that are currently ob-
we studied the HPMC receptor of AGE expression (RAGE), served in long-term PD patients [1, 2]. Exposure to stan-and analyzed the results of AGE–RAGE interaction on adhe-
dard peritoneal fluids may induce a kind of ‘chemical’sion molecule expression and leukocyte binding.
Methods. RAGE was detected by FACS analysis, and RAGE peritonitis, which could be responsible for a reduction
mRNA by reverse transcription–polymerase chain reaction in the number of mesothelial cells and the loss of dialysis
(RT–PCR). Vascular and intercellular cell adhesion molecule function [2]. The mesothelial cells and peritoneal fibro-(VCAM-1 and ICAM-1) expression was measured by a known
blasts function as a filtration barrier, but also controlradiometric technique under basal conditions, after the addi-
tion of an AGE-specific compound, Nε-carboxylmethyllysine intraperitoneal inflammation. The activation of inflam-
(CML–albumin). Leukocyte adhesion on HPMC was analyzed mation within the body results from a complex series of
by videomicroscopy after HPMC stimulation. cellular and humoral reactions. The effect of direct toxic-Results. RAGE protein was detected on HPMC, and RAGE
ity of the peritoneal fluid on mesothelial cells has beenmRNA was evidenced by RT-PCR. VCAM-1 expression was
stimulated by CML-albumin (P  0.01), while ICAM-1 was suggested as one of the possible factors affecting perito-
unchanged. By blocking the AGE–RAGE interaction, anti- neal barrier function [3–6]. Recently, several studies have
RAGE antibodies or recombinant RAGE inhibited the in-
focused attention on a particular class of ‘chemical’ com-crease in VCAM-1 expression. CML–albumin stimulation po-
pounds, the advanced glycation end-products [4, 7–14].tentiated leukocyte adhesion to HPMC (P 0.001). This effect
was prevented by the incubation of leukocytes with recombi- Advanced glycation end-products (AGEs) result from
nant VCAM-1 (P  0.001). the reaction between carbohydrates and the free amino
Conclusions. AGE binding to RAGE stimulated mesothe-
group of proteins, which is followed by complex molecu-lial cell activity, and resulted in the overexpression of VCAM-1,
lar rearrangements. This class of molecule is the resulta structure for leukocyte adhesion. The AGE–RAGE interac-
tion resulted in HPMC activation, which may promote local of glycooxidation, and includes early, intermediate and
inflammation, and thus is implicated in the peritoneal injury late glycation products. AGE levels are increased in the
found in long-term PD patients.
case of diabetes mellitus, renal failure, or aging [15–21].
The formation of AGEs, or the Maillard reaction, con-
sists of a series of chemical non-enzymatic glycosylationIn the 1980s when peritoneal dialysis (PD) was ex-
or glycation steps [22]. Antigenic AGE compounds suchtended to the treatment of end-stage renal disease, it
as pentosidine and Nε-carboxymethyllysine (CML) cancould only be used for a short duration because of the
be detected in humans. CML is the ligand with the high-
est affinity for the best characterized AGE receptor,Key words: peritoneal dialysis, glycation, inflammation, advanced gly-
cation end products, leukocytes. RAGE [23]. RAGE is a member of the immunoglobulin
superfamily, and is expressed on endothelial, smoothReceived for publication March 27, 2001
muscle, and mesangial cells, on mononuclear phagocytesand in revised form August 28, 2001
Accepted for publication August 30, 2001 and on developing neurons [23–25].
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be at the origin of the glucose-derived products that maintained in exponential growth from a seeding density
of 2  105 cells/mL to a maximum density of 1.5  106can form AGEs [13, 26]. AGE deposits also have been
observed in histological specimens from PD patients cells/mL. Adhesion molecule expression on HL60 was
measured as previously described [30].[11, 27]. To determine whether AGEs could alter meso-
thelial cell function through binding to a specific recep-
Glycated proteins, RAGE antibody andtor, human peritoneal mesothelial cells (HPMC) were
recombinant moleculescultured with the subsequent expression of RAGE, and
it was possible to show that AGE binding resulted in the Nε-carboxymethyllysine–albumin was prepared as fol-
lows: ovalbumin and sodium cyanoborohydride were dis-potentiation of vascular cell adhesion molecule (VCAM-1)
expression and leukocyte adhesion. As most of the in- solved in phosphate-buffered saline (PBS). Glyoxylic
acid was added, and after 16 hours incubation the solu-vestigations on AGE–RAGE interactions have been
conducted on human umbilical vein endothelial cells tion was dialyzed against PBS [31]. The degree of CML
glycation was determined by 2,4,6-trinitrobenzene sul-(HUVEC), we then compared the HUVEC and HPMC
reactions to AGEs [18, 23, 28, 29]. fonic acid, which was used to identify the modified lysine
in the preparation [32]. Albumin was used as the control,
and subjected to the same procedure except for the omis-
METHODS
sion of glyoxylic acid. Albumin solutions were passed
Cell culture through Detoxi-Gel columns to remove possible endo-
toxin contamination (Pierce, Rockford, IL, USA). TheHuman umbilical vein endothelial cells were grown
and identified as previously described [15]. Cells were endotoxin levels in the different preparations were less
than 1 endotoxin unit/mg of protein.obtained by enzymatic digestion with collagenase (Wor-
thington Biochemical Corporation, Freehold, NJ, USA) For RAGE antibody production, rat RAGE was puri-
fied to homogeneity from rat lung powder by the meth-and cultured in M199 medium with glutamine 2 mmol/L,
Hepes 15 mmol/L, gentamicin 50 g/mL, amphoteri- ods previously described for bovine RAGE, and this
corresponded to the amino-terminal two-thirds of thecin B 250 g/100 mL (Gibco Life Technologies, Grand
Island, NY, USA) supplemented with human serum molecule [23]. Purified rat RAGE was used to immunize
rabbits according to previously described methods [33].(15% vol/vol).
Human peritoneal mesothelial cells were isolated from This monospecific anti-RAGE IgG was purified by affin-
ity chromatography with immobilized protein A.freshly obtained omental tissue from different patients
who had undergone elective abdominal surgery. Subjects The production of recombinant sRAGE has been de-
scribed previously [33]. Briefly, RAGE was cloned fromwith diabetes mellitus, abdominal inflammation or diffuse
carcinoma were excluded from the study. The study was a rat lung cDNA library, and recombinant rat sRAGE
(rR-RAGE) was produced by baculovirus-transfectedconducted in accordance with the guidelines laid down in
the revised Tokyo version of the Declaration of Helsinki, insect cells (Spodoptera frugiperda or Sf9). The resulting
protein corresponded to the RAGE extracellular do-and with the rules of our institution. Omental specimens
were washed and cut into small pieces, then incubated main and acted by binding to AGEs, thereby blocking
their interaction with endogenous RAGE [33, 34].under agitation for 20 minutes at 37C with collagenase
(0.2%). The cells were seeded and cultured in M199 me- A DNA fragment coding for the first three Ig-like
domains of rat VCAM-1 was obtained from a rat lungdium with glutamine 2 mmol/L, Hepes 15 mmol/L, genta-
micin 50 g/mL, amphotericin B 250 g/100 mL, 10% cDNA library (Clontech, Palo Alto, CA, USA), using
a PCR technique. The purified recombinant solublefetal calf serum (FCS; Dutscher Brumath, France), and
endothelial cell growth factor (ECGF) 5 g/mL (Sigma, VCAM-1 (rR-VCAM-1) had a molecular weight of
approximately 35 kD and cross-reacted with humanSt. Louis, MO, USA) in flasks (Costar, Cambridge, MA,
USA) that had previously been coated with gelatin 0.2% VCAM-1 antibody, as previously described [34].
(Difco, Detroit, MI, USA). The medium was changed
Flow cytometry analysisafter 12 hours and subsequently every 48 hours until the
cells reached confluence (7 to 12 days). For all experi- Human peritoneal mesothelial cell characterization
and RAGE expression on the HPMC surface were studiedments, cells were obtained from primary culture, or from
under four passages. by flow cytometry, as previously described [35, 36]. Cells
were harvested and then washed twice with PBS. ForThe human promyelocytic cell line (HL60) was ob-
tained from the American Type Culture Collection each experiment, 2  105 cells were incubated for 30
minutes at 4C with primary antibodies: mouse anti-hu-(Rockville, MD, USA). Cells were cultured at 37C with
5% CO2, in RPMI 1640 medium with FCS (10%), gluta- man cytokeratin 18, anti-human propyl 4-hydroxylase
(anti-fibroblast) monoclonal antibodies, rabbit anti-humanmine 2 mmol/L, Hepes 15 mmol/L, gentamicin 50g/mL,
and amphotericin B 250 g/100 mL. HL60 cells were von Willebrand factor (vWF) polyclonal antibody (Dako,
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Golstrup, Denmark), mouse anti-human platelet endo- plification) [37]. PCR conditions were as follows: 12 min-
utes at 95C, then 35 cycles of one minute at 94C, onethelial cell adhesion molecule (PECAM-1) monoclonal
minute at 55C, one minute at 72C, and then seven minutesantibody (R&D Systems, Abingdon, UK). Antibody
at 72C. The HPMC and HUVEC products were subse-binding was evidenced by FITC-conjugated secondary
quently electrophoresed (acrylamide gel 8%), stained,antibodies (Immunotech, Marseille, France). Immuno-
and compared to DNA standards.fluorescence intensity was quantified by FACS (FacScan;
Becton Dickinson, Mountain View, CA, USA). For each
Adhesion molecule expression andantibody, 5000 events were recorded. The results were
leukocyte adhesionpresented as the mean fluorescence intensity (MFI) ex-
Adhesion molecule expression was studied by a pre-pressed as arbitrary units of fluorescence (AUF). For
viously described radiometric technique [36]. The con-negative control, primary antibody was omitted.
fluent HPMC monolayer was stimulated either by cyto-
RAGE expression kines [tumor necrosis factor alpha (TNF-) 5 ng/mL, or
interleukin-1 beta (IL-1) 50 U/mL] or glycated proteinsReceptor of AGE membrane expression on HPMC
(CML–albumin at 50 g/mL) for 4, 16 or 24 hours beforeor HUVEC in suspension was determined by immuno-
quantification of E-selectin (CD62E), VCAM-1 (CD106)histochemical staining or by flow cytometry.
and ICAM-1 (CD54; R & D Systems), respectively. InFor immunohistochemical studies, peritoneal biopsy
some experiments, rR-RAGE (60 g/mL), anti-RAGEspecimens with no signs of pathological change were
IgG, or non-immune rat IgG (100 g/mL; Sigma) weretaken from three patients (one 59-year-old man and two
added. After two washes, the monolayers were incubatedwomen, aged 42 and 57 years, respectively) and analyzed.
for one hour with specific antibodies. Binding was shownSpecimens were routinely fixed in formalin and embed-
with a second antibody, the IgG F(ab)2 fragment (Amer-ded in paraffin. Prior to immunohistochemical study,
sham Pharmacia Biotech, Buckinghamshire, UK). Radio-5-m thick paraffin sections were deparaffinized in xy-
activity was measured in a gamma counter (Beckman LSlene and rehydrated in graded alcohol. For epitope re-
6000SC, Fullerton, CA, USA). Results were expressed intrieval, microwave pretreatment (400 W for 20 minutes in
counts per minute (cpm).10 mmol/L sodium citrate buffer, pH 6.0) was employed.
For the study of leukocyte adhesion, confluent HPMCSlides were then exposed to 1% hydrogen peroxide di-
cultured in 35-mm plastic dishes were stimulated by cyto-luted in methanol for 30 minutes at room temperature
kines (TNF- 5 ng/mL, and IL-1 50 U/mL) or CML–to block endogenous peroxidase activity. This was fol-
albumin (50 g/mL) for 16 hours. For the inhibition ex-
lowed by rehydration in PBS and incubation in a block- periments, HPMC were preincubated with rR-RAGE
ing solution (pig serum diluted 1:5 in PBS) for 10 minutes (60g/mL), anti-RAGE IgG (100g/mL) or non-immune
at room temperature. The latter solution was removed rat IgG (100 g/mL). Preincubation of leukocytes with
from the slides using filter paper, and anti-RAGE pri- rR-VCAM-1 (200g/mL) or non-immune rat IgG (200g/
mary antibody was added to the sections and left over- mL) was performed to inhibit leukocyte adhesion. After
night at room temperature. After removing unbound stimulation, HPMC were washed and then incubated for
antibody by several washes with PBS, the remaining one hour at 37C with human blood leukocytes or HL60
specifically-bound antibody was detected via the Dako cells, per dish 1 106. Non-adherent leukocyte cells were
ABC method, as visualized by aminoethylcarbazol. Sec- removed by successive washings. Leukocyte adhesion was
tions were lightly counterstained with hematoxylin and determined by videomicroscopy and automatic counting
eosin, and analyzed by standard light microscopy. in a 0.1-mm2 field. The results were expressed in leuko-
For the study of RAGE mRNA, RNA was extracted cyte/mm2 as the mean of 30 determinations per 35-mm
from HPMC and HUVEC (1.25 106), using RNAble re- plastic dish.
agent (Eurobio, Les Ulis, France) according to the manu-
Statistical analysisfacturer’s instructions. Total RNA (18 g) was treated
with 5 U RNase-free DNase I (Genhunter, Nashville, Results have been presented as the mean  standard
TN, USA) for one hour at 37C to digest genomic DNA. error of the mean (SEM), or as the mean  standard
The purified RNA was adjusted to 1 g/L and checked deviation (SD). Statistical significance was determined
for integrity by standard agarose gel electrophoresis. Re- using a one-way analysis of variance (ANOVA) followed
verse transcription was performed using OligodT prim- by the parametric Dunnett’s test.
ers, following the manufacturer’s instructions (Promega,
Charbonnie`res, France). PCR primers were designed to
RESULTSamplify a 469-base pair (bp) region located in the RAGE
Characterization of human peritoneal mesothelial cellscoding region: sense primer 5-CCCTTCTCATTAGG
CACCAG-3, antisense primer 5-CAGGAATGGAA The HPMC were bipolar and elongated in form during
the initial growth phase, but immediately prior to andAGGAGACCA-3 (primers designed for quantitative am-
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Fig. 1. Receptor of advanced glycation end-product (RAGE) expression on human peritoneal mesothelial cells (HPMC) and human unbilical
vein endothelial cells (HUVEC) obtained with anti-RAGE antibody. (A) Typical flow cytometry profiles. (B) Mean fluorescence intensity (MFI)
in four sets of experiments, expressed in AUF. The whiskers denote the standard deviation (*P  0.05). (C) Polymerase chain reaction (PCR)
amplification of reverse transcripted (RT) RAGE mRNA from HPMC and HUVEC. RAGE mRNA from HPMC and HUVEC had a similar
electrophoretic profile and was reproducible in different cell cultures (two sets of experiments). The arrow indicates the amplified region of 469
bp located in the coding region of RAGE.
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at confluence, they adopted a polygonal cobblestone ap-
pearance characteristic of epithelial cells, and formed a
monolayer.
Immunofluorescent staining of confluent cells demon-
strated that after permeabilization, HPMC were clearly
stained by anti-cytokeratin 18 but only weakly stained
with anti-vWF. After labeling with anti-vWF antibody
the HUVEC fluorescence was intense with a granular ap-
pearance, while HPMC fluorescence was weak and diffuse.
Human peritoneal mesothelial cells were also tested
in suspension and the results analyzed by flow cytometry.
Anti-propyl 4-hydroxylase (anti-fibroblastic agent) did
not react with HPMC or HUVEC, while HPMC and
HUVEC were positively stained by anti-vimentin. HPMC
but not HUVEC were labeled by anti-cytokeratin 18
(MFI, 132  17 AUF). The fluorescence intensity of
Fig. 2. Immunohistochemical staining of mesothelial cells with anti-HUVEC after labeling with anti-vWF antibody was sig-
RAGE antibody. (A) Histomorphology of normal human peritonealnificantly higher than that of HPMC (913  108 com- mesothelial cells (59-year old male) stained with hematoxylin and eosin
pared to 61  15 AUF, P  0.001). A clear distinction (H&E). (B) Diffuse intracytoplasmatic staining of mesothelial cells
(arrow) is evident at high magnification after immunohistochemicalbetween the two cell types was confirmed by the absence
staining with anti-RAGE antibody (4500).of reaction of HPMC with anti-PECAM-1. For compari-
son, HUVEC exhibited a high fluorescence intensity
(724  46 AUF).
albumin (P  0.01; Fig. 3B). CML–albumin potentiated
RAGE expression and mRNA determination the expression of VCAM-1 on mesothelial cells in a con-
centration-dependent manner (10  7% for 25 g/mL,The presence of RAGE on HPMC and HUVEC was
demonstrated by flow cytometry analysis using a specific 58  5% for 50 g/mL and 50  8% for 100 g/mL,
respectively). Since maximum stimulation was achievedanti-RAGE antibody (Fig. 1A). The percentage of fluo-
rescent cells was similar, while HUVEC expressed RAGE with 50 g/mL CML–albumin, this concentration was
used for the following experiments. Anti-RAGE anti-to a higher extent than HPMC (110  17 vs. 60  6
AUF, respectively, P  0.05; Fig. 1B). body inhibited VCAM-1 expression according to the
concentration of antibody added (25% for 20 g/mL,Human peritoneal mesothelial cells and HUVEC
mRNA obtained from two different cultures were ampli- 75% for 50g/mL and 85% for 100g/mL, respectively).
Addition of CML–albumin preincubated with rR-RAGEfied by RT–PCR. Electrophoresis on an 8% polyacryl-
amide gel displayed a band corresponding to RAGE or anti-RAGE antibody to block AGE binding to HPMC
prevented the increase of VCAM-1 expression (Fig. 3C).mRNA located in the region of 469 bp (Fig. 1C).
The immunohistochemical demonstration of RAGE Stimulation of HPMC by CML–albumin resulted in a
fivefold increase in the adhesion of human blood leuko-in human mesothelial cells is shown in Figure 2. As can
be observed at high magnification, peritoneal mesothe- cytes, and to a larger extent (that is, 35-fold) when HPMC
were stimulated by TNF-. Since HL60 cells possesslial cells exhibit a diffuse intracytoplasmic staining with
anti-RAGE antibody (Fig. 2B). Analogous results also most of the adhesive properties of monocytes and have
been extensively used, we decided to select this cell linewere obtained in normal peritoneal biopsies from two
other patients (data not shown). to assess adhesion to HPMC under various experimental
conditions [30]. Leukocytes adhered to the cultured
Adhesion molecule expression and HPMC confluent monolayer (200  14 HL60/mm2), and
leukocyte adhesion the extent of adhesion was increased when HPMC were
stimulated by CML–albumin (316  24 HL60/mm2, P E-selectin was not expressed on HPMC under basal
conditions, nor after stimulation by cytokines (TNF-, 0.001; Fig. 4). The preincubation of HPMC with rR-
RAGE or anti-RAGE IgG to block AGE binding toIL-1) or CML–albumin. ICAM-1 was present on HPMC
under basal conditions, and was overexpressed after HPMC prevented the increase of leukocyte adhesion
induced by CML–albumin (P 0.001). When HL60 cellsstimulation by TNF- (P  0.01) and IL-1 (P  0.05),
but was not enhanced by incubation with CML–albumin were preincubated with rR-VCAM-1, the increase in
adhesion to HPMC was prevented (141  14, P  0.001)(Fig. 3A). VCAM-1 was detected in the absence of stimu-
lation, and its expression was potentiated by TNF- (P while preincubation with a control protein (IgG) did not
have any effect.0.001) or IL-1 (P 0.01), and by incubation with CML–
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Fig. 3. Adhesion molecule expression on HPMC. Intercellular (ICAM-1; A) and vascular (VCAM-1; B) cell adhesion molecule expressions were
studied under basal conditions or after stimulation (TNF- 5 ng/mL, IL-1 50 U/mL and CML-albumin 50 g/mL). All results are expressed in
cpm and presented as the mean  SEM of two series of experiments for ICAM-1 and four series for VCAM-1, all carried out in quadruplicate
(*P  0.05; **P  0.01; ***P  0.001). (C) VCAM-1 expression after preincubation of HPMC with anti-RAGE IgG (100 g/mL) or rR-RAGE
(60 g/mL).
DISCUSSION antibody or CML–albumin with recombinant RAGE
both inhibited the stimulation of VCAM-1 induced byIn this study, RAGE mRNA production by HPMC
AGEs, thereby reinforcing the hypothesis that the reac-was confirmed (abstract; Cooker et al, Nephrology 3:S62,
tion was mediated by the AGE–RAGE interaction. The1997), and it was demonstrated that the protein is ex-
presence of VCAM-1 on unstimulated HPMC and itspressed at the cell membrane level, and moreover is
enhancement following cytokine treatment has beenfunctional. Since endothelial cells and other cell types
demonstrated previously [38]. Our results showed that inalso can express RAGE, we clearly demonstrated that
addition to inflammatory cytokines, AGEs can modulatethe cell population studied consisted of mesothelial cells.
VCAM-1 expression. ICAM-1 is expressed on HPMC,The presence of RAGE on cultured HPMC was not an
and as we observed is potentiated by TNF- stimulationartifact, since it has been confirmed on human peritoneal
[39, 40]. Contrary to VCAM-1, ICAM-1 expression onspecimens.
HPMC was not affected by addition of CML–albumin.After stimulation by CML–albumin, the well-defined
This different effect regarding adhesion molecule expres-AGE ligand of RAGE, the expression of VCAM-1 was
potentiated. Preincubation of HPMC with anti-RAGE sion is similar to the results observed with HUVEC,
Boulanger et al: AGE–RAGE in mesothelial cells154
fluids of several mediators that are involved in the inflam-
matory reaction such as prostaglandins, leukotrienes, cy-
tokines IL-1, IL-1, IL-6, IL-8, and TNF- [3, 5, 46].
Other molecules that modulate mesothelial cell, fibro-
blast, and macrophage function can participate in protein
synthesis and also in protein degradation [transforming
growth factor- (TGF-), and matrix metalloproteinase
9 (MMP-9)] [5, 47]. In addition, the activation of coagula-
tion by tissue factor synthesis, or the reduction of plas-
minogen activator inhibitor-1 (PAI-1) may contribute to
the inflammatory reaction [46].
The AGE–RAGE interaction has been shown to gen-
erate reactive oxygen intermediates that could affect
peritoneal function [29]. RAGE is a multi-ligand recep-
tor and a signal transduction receptor for ENRAGE
and related members of the S100/calgranulin family of
proinflammatory cytokines [48].
The present study on the proinflammatory effects ofFig. 4. Leukocyte adhesion. Leukocyte adhesion on HPMC was mea-
sured under basal conditions and after stimulation by CML-albumin AGEs on mesothelial cells has indicated the desirability
(50 g/mL) with or without preincubation of HPMC with rR-RAGE of using PD solutions containing decreased amounts of(60 g/mL) or anti-RAGE IgG (100 g/mL) for blocking AGE binding
glucose or glucose derivatives, leading to reduced AGEto mesothelial RAGE. Preincubation of leukocytes with rR-VCAM-1
(200 g/mL) also was carried out to block leukocyte adhesion. The formation. Blockade of AGE–RAGE binding by recom-
results of three different series of experiments are expressed in leuko- binant RAGE or RAGE antibody studied in in vitro orcytes/mm2 and presented as the mean  SEM of 30 determinations (NS
in animal experiments has demonstrated the efficacy ofis non-significant; ***P  0.001).
inhibiting AGE–RAGE interactions [18, 29, 48–50].
Products such as aminoguanidine or OPB-9195 are
known to limit the formation of AGEs by inhibiting the
and suggests that the transduction pathways and gene production of glyoxal, methylglyoxal and 3-deoxygluco-
transcription regulation differ after cytokine or AGE sone. However, these compounds are known to have
stimulation respectively [29, 41, 42]. certain adverse side effects [51]. A novel class of drugs
Vascular cellular adhesion molecule-1 expression after termed AGE cross-link breakers, which includes Alt 711
AGE stimulation is accompanied by enhanced leukocyte and N-phenacylthiazolium bromide, is now being investi-
adhesion, indicating that this mechanism may participate gated and may represent an alternative therapeutic ap-
in the inflammatory process and could have an influence proach [52, 53].
on HPMC or monocyte function, especially with regards The mechanism underlying the peritoneal modifica-
to the peritoneal macrophages that can be activated by tions induced by glycated proteins appears to be extremely
AGEs and produce TNF- [43]. Adherent leukocytes complex, and related to cell–cell interactions and a net-
may infiltrate and migrate through the mesothelial cells; work of mediators. The present study should provide
in addition, they can produce inflammatory mediators additional information on the complex pathophysiology
and/or modulate protein remodeling, as is the case in of the alterations in peritoneal barrier function and host
atherosclerotic plaque formation [18, 28, 44]. During PD, defense mechanisms in long-term PD patients.
at least two factors may lead to AGE formation: renal
failure and high glucose concentrations in PD solutions.
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